At James F. Humphreys & Associates, L.C., we believe that you should be informed of all the potential health effects before taking any new weight loss medication. Our firm is reviewing cases for the weight-loss drug Belviq to help consumers like you fight back against dangerous drugs.
Belviq
Belviq is a prescription weight-loss medication designed to help people with obesity feel full while consuming fewer calories. While the drug was approved by the FDA and put on the market, a clinical study for safety and efficacy later discovered that the drug possibly increases the risk of multiple forms of cancer, including:
- Pancreatic
- Colorectal
- Lung
In January 2020, the FDA announced it was reviewing the clinical trial data and alerted the public about a possible cancer risk based on its preliminary analysis of the data. In February 2020, it asked the manufacturer Eisai, Inc. to voluntarily withdraw the drug from the U.S. market because the clinical trial data showed an increased risk of cancer, including cancers of the lung, pancreas, colon and rectum. Health professionals were advised to stop prescribing and dispensing the drug.
If you believe that his medication has hurt you or a loved one, contact James F. Humphreys & Associates, L.C. for a free consultation. We are ready to research your case and provide you with thorough and vigorous representation.
Toll Free: +1 (877) 341-2595
Email: jhumphreys@jfhumphreys.com
